533054070	533054070	CD	B-NP	O
|	|	NN	I-NP	O
P	P	NN	I-NP	O
|	|	NN	I-NP	O
79191622	79191622	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
4001405	4001405	CD	B-NP	O
|	|	CC	I-NP	O
10/21/2007	10/21/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
fibrosis	fibrosis	NN	I-NP	O
|	|	NN	I-NP	O
Unsigned	Unsigned	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
7/22/2007	7/22/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Unsigned	Unsigned	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/5/2007	8/5/2007	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
TALSKY	TALSKY	NN	B-NP	O
,	,	,	O	O
JARVIS	JARVIS	NNP	B-NP	O
CLAIR	CLAIR	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Diabetes	Diabetes	NNP	B-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
DIAGNOSES	DIAGNOSES	NNS	I-NP	O
:	:	:	O	O
Cirrhosis	Cirrhosis	NN	B-NP	O
and	and	CC	I-NP	O
IPF	IPF	NN	I-NP	B-protein
.	.	.	O	O

SERVICES	SERVICES	NNS	B-NP	O
:	:	:	O	O
GMS	GMS	NNP	B-NP	O
Chi	Chi	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	NNP	B-NP	O
ILLNESS	ILLNESS	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
76-year-old	76-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
IPF	IPF	NN	B-NP	B-protein
,	,	,	O	O
on	on	IN	B-PP	O
home	home	NN	B-NP	O
oxygen	oxygen	NN	I-NP	O
at	at	IN	B-PP	O
3	3	CD	B-NP	O
l	l	NN	I-NP	O
nasal	nasal	JJ	I-NP	O
cannula	cannula	NN	I-NP	O
at	at	IN	B-PP	O
baseline	baseline	NN	B-NP	O
,	,	,	O	O
cryptogenic	cryptogenic	JJ	B-NP	O
cirrhosis	cirrhosis	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
insulin-dependent	insulin-dependent	JJ	B-NP	B-protein
diabetes	diabetes	NN	I-NP	I-protein
mellitus	mellitus	NN	I-NP	I-protein
who	who	WP	B-NP	I-protein
was	be	VBD	B-VP	O
recently	recently	RB	I-VP	O
admitted	admit	VBN	I-VP	O
from	from	IN	B-PP	O
9/10/07	9/10/07	CD	B-NP	O
through	through	IN	B-PP	O
4/28/07	4/28/07	CD	B-NP	O
for	for	IN	B-PP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
and	and	CC	I-NP	O
volume	volume	NN	I-NP	O
overload	overload	RB	B-ADVP	O
,	,	,	O	O
who	who	WP	B-NP	O
presented	present	VBD	B-VP	O
with	with	IN	B-PP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
and	and	CC	I-NP	O
weight	weight	NN	I-NP	O
gain	gain	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
previous	previous	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
spontaneous	spontaneous	JJ	B-NP	O
bacterial	bacterial	JJ	I-NP	O
peritonitis	peritonitis	NN	I-NP	O
based	base	VBN	B-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
diagnostic	diagnostic	JJ	I-NP	O
paracentesis	paracentesis	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
250	250	CD	I-NP	O
neutrophils	neutrophil	NNS	I-NP	B-cell_type
.	.	.	O	O

During	During	IN	B-PP	O
that	that	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
SBP	SBP	NN	I-NP	B-protein
and	and	CC	O	O
was	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
oral	oral	JJ	B-NP	O
cefpodoxime	cefpodoxime	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
during	during	IN	B-PP	O
that	that	DT	B-NP	O
previous	previous	JJ	I-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
hyperglycemic	hyperglycemic	JJ	B-ADJP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
Lantus	Lantus	NNP	B-NP	O
90	90	CD	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
aspartate	aspartate	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
home	home	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
blood	blood	NN	I-NP	O
pressures	pressure	NNS	I-NP	O
were	be	VBD	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
200	200	CD	I-NP	B-DNA
to	to	TO	I-NP	I-DNA
300s	300s	CD	I-NP	I-DNA
and	and	CC	O	O
at	at	IN	B-PP	O
times	time	NNS	B-NP	O
even	even	RB	B-ADJP	O
higher	higher	RBR	I-ADJP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
week	week	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
gained	gain	VBD	B-VP	O
somewhere	somewhere	RB	B-ADVP	O
from	from	IN	B-PP	O
about	about	RB	B-NP	O
8	8	CD	I-NP	O
to	to	TO	I-NP	O
10	10	CD	I-NP	O
pounds	pound	NNS	I-NP	O
with	with	IN	B-PP	O
increasing	increase	VBG	B-VP	O
abdominal	abdominal	JJ	B-NP	O
girth	girth	NN	I-NP	O
and	and	CC	O	O
lower	low	JJR	B-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
fingersticks	fingerstick	NNS	I-NP	O
were	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
elevated	elevate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
300s	300	NNS	I-NP	O
and	and	CC	O	O
so	so	RB	B-ADVP	O
her	her	PRP$	B-NP	O
Lantus	Lantus	NNP	I-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
from	from	IN	B-PP	O
90	90	CD	B-NP	O
units	unit	NNS	I-NP	O
daily	daily	RB	B-ADVP	O
to	to	TO	B-PP	O
100	100	CD	B-NP	O
units	unit	NNS	I-NP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
visiting	visit	VBG	I-NP	O
nurse	nurse	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
previously	previously	RB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
up	up	RB	B-NP	O
to	to	TO	I-NP	O
80	80	CD	I-NP	O
mg	mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
also	also	RB	I-ADVP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
visiting	visit	VBG	I-NP	O
nurse	nurse	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
additional	additional	JJ	I-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
oxygen	oxygen	NN	I-NP	O
sat	sat	NN	I-NP	O
was	be	VBD	B-VP	O
unchanged	unchanged	JJ	B-ADJP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
O2	O2	NN	B-NP	B-protein
.	.	.	O	O

She	She	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
cough	cough	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
no	no	DT	B-NP	O
fevers	fever	NNS	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
diarrhea	diarrhea	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
finished	finish	VBN	I-VP	O
a	a	DT	B-NP	O
7-day	7-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
cefpodoxime	cefpodoxime	NN	B-NP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
mental	mental	JJ	I-NP	O
status	status	NN	I-NP	O
was	be	VBD	B-VP	O
unchanged	unchanged	JJ	B-ADJP	O
as	as	IN	B-SBAR	O
felt	feel	VBN	B-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
daughter	daughter	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Idiopathic	Idiopathic	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
fibrosis	fibrosis	NN	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
3	3	CD	B-NP	O
L	L	NN	I-NP	O
home	home	NN	I-NP	O
O2	O2	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Insulin-dependent	Insulin-dependent	JJ	B-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Cryptogenic	Cryptogenic	JJ	B-NP	O
cirrhosis	cirrhosis	NN	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
ascites	ascite	NNS	B-NP	O
and	and	CC	O	O
esophageal	esophageal	JJ	B-NP	O
varices	varix	NNS	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
possible	possible	JJ	B-NP	O
hepatic	hepatic	JJ	I-NP	O
encephalopathy	encephalopathy	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	NN	I-NP	O
cholecystectomy	cholecystectomy	NN	I-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
AT	AT	NN	I-NP	O
HOME	HOME	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Fosamax	Fosamax	NN	B-NP	O
35	35	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Caltrate	Caltrate	VB	B-VP	O
600	600	CD	B-NP	O
mg	mg	NN	I-NP	O
plus	plus	CC	O	O
D	D	NN	B-NP	O
1	1	CD	I-NP	O
tabler	tabler	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Cefpodoxime	Cefpodoxime	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
completed	complete	VBN	I-VP	O
the	the	DT	B-NP	O
day	day	NN	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Clotrimazole	Clotrimazole	NN	B-NP	O
troche	troche	NN	I-NP	O
orally	orally	RB	B-ADVP	O
four	four	CD	I-ADVP	O
times	time	NNS	I-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	B-protein
80	80	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
b.i.d.	b.i.d.	NN	I-NP	I-protein
7	7	CD	I-NP	I-protein
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
100	100	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
every	every	DT	B-NP	O
morning	morning	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Combivent	Combivent	VB	B-VP	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
4	4	CD	B-NP	O
times	time	NNS	I-NP	O
daily	daily	RB	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Lisinopril	Lisinopril	NNP	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Nadolol	Nadolol	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Prilosec	Prilosec	RB	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Bactrim	Bactrim	JJ	B-NP	O
DS	DS	NN	I-NP	O
1	1	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
known	know	VBN	I-NP	O
drug	drug	NN	I-NP	O
allergies	allergy	NNS	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
lives	live	VBZ	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
daughter	daughter	NN	I-NP	O
,	,	,	O	O
Lescano	Lescano	NNP	B-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
her	her	PRP$	B-NP	O
healthcare	healthcare	NN	I-NP	O
proxy	proxy	NN	I-NP	O
and	and	CC	O	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
reached	reach	VBN	I-VP	O
at	at	IN	B-PP	O
976-115-0167	976-115-0167	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
never	never	RB	B-ADVP	O
drunk	drunk	JJ	B-NP	O
alcohol	alcohol	NN	I-NP	O
,	,	,	O	O
smoked	smoke	VBN	B-VP	O
,	,	,	O	O
and	and	CC	O	O
never	never	RB	B-ADVP	O
used	use	VBN	B-VP	O
any	any	DT	B-NP	O
illicit	illicit	JJ	I-NP	O
drugs	drug	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
originally	originally	RB	B-ADVP	O
from	from	IN	B-PP	O
Clear	Clear	JJ	B-NP	O
A	A	NN	I-NP	O
Rieholl	Rieholl	NN	I-NP	O
and	and	CC	I-NP	O
Spanish-speaking	Spanish-speaking	NN	I-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
Unremarkable	Unremarkable	JJ	B-ADJP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NNP	B-NP	O
EXAMINATION	EXAMINATION	NNP	I-NP	O
ON	ON	NNP	I-NP	O
ADMISSION	ADMISSION	NNP	I-NP	O
:	:	:	O	O
VITAL	VITAL	JJ	B-NP	O
SIGNS	SIGNS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
.	.	.	O	O

Temperature	Temperature	NN	B-NP	O
was	be	VBD	B-VP	O
96.9	96.9	CD	B-NP	O
,	,	,	O	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
62	62	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
90/50	90/50	CD	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
breathing	breathe	VBG	I-VP	O
16	16	CD	B-NP	O
times	time	NNS	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
saturating	saturate	VBG	I-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
baseline	baseline	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
oxygen	oxygen	NN	B-NP	O
at	at	IN	B-PP	O
3	3	CD	B-NP	O
L.	L.	NNP	I-NP	O
HEENT	HEENT	NNP	I-NP	O
:	:	:	O	O
Notable	Notable	JJ	B-ADJP	O
for	for	IN	B-PP	O
tongue	tongue	NN	B-NP	O
that	that	WDT	B-NP	O
showed	show	VBD	B-VP	O
thrush	thrush	NN	B-NP	O
.	.	.	O	O

NECK	NECK	NN	B-NP	O
:	:	:	O	O
JVP	JVP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
difficult	difficult	JJ	B-ADJP	O
to	to	TO	B-PP	O
asses	ass	NNS	B-NP	O
but	but	CC	O	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
slightly	slightly	RB	B-ADJP	O
elevated	elevated	JJ	I-ADJP	O
.	.	.	O	O

There	There	EX	B-NP	O
was	be	VBD	B-VP	O
no	no	DT	B-NP	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O
.	.	.	O	O

LUNGS	LUNGS	NNS	B-NP	O
:	:	:	O	O
Dry	Dry	JJ	B-NP	O
inspiratory	inspiratory	JJ	I-NP	O
crackles	crackle	NNS	I-NP	O
at	at	IN	B-PP	O
both	both	DT	B-NP	O
bases	base	NNS	I-NP	O
.	.	.	O	O

CARDIOVASCULAR	CARDIOVASCULAR	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
slow	slow	JJ	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
S1	S1	NN	I-NP	B-protein
and	and	CC	I-NP	O
S2	S2	NN	I-NP	B-protein
.	.	.	O	O

No	No	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
rubs	rub	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
gallops	gallop	NNS	B-NP	O
.	.	.	O	O

ABDOMEN	ABDOMEN	NN	B-NP	O
:	:	:	O	O
Slightly	Slightly	RB	B-ADJP	O
distended	distended	JJ	I-ADJP	O
,	,	,	O	O
soft	soft	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
nontender	nontender	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
guarding	guarding	NN	I-NP	O
and	and	CC	O	O
positive	positive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

EXTREMITIES	EXTREMITIES	NNS	B-NP	O
:	:	:	O	O
Remarkable	Remarkable	JJ	B-ADJP	O
for	for	IN	B-PP	O
3	3	CD	B-NP	O
+	+	SYM	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
pitted	pit	VBN	B-VP	O
,	,	,	O	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
knees	knee	NNS	I-NP	O
.	.	.	O	O

NEUROLOGIC	NEUROLOGIC	NN	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
asterixis	asterixis	NN	I-NP	O
and	and	CC	O	O
no	no	DT	B-NP	O
focal	focal	JJ	I-NP	O
deficits	deficit	NNS	I-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
DATA	DATA	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
Electrolytes	Electrolyte	NNS	B-NP	O
were	be	VBD	B-VP	O
remarkable	remarkable	JJ	B-ADJP	O
for	for	IN	B-PP	O
BUN	BUN	NN	B-NP	B-protein
and	and	CC	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
65/1	65/1	CD	B-NP	O
.6	.6	CD	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
potassium	potassium	NN	I-NP	O
of	of	IN	B-PP	O
6.0	6.0	CD	B-NP	O
.	.	.	O	O

Albumin	Albumin	NN	B-NP	B-protein
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
2.6	2.6	CD	B-NP	O
.	.	.	O	O

CBC	CBC	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
8.51	8.51	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	O
of	of	IN	B-PP	O
34.7	34.7	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
platelets	platelet	NNS	B-NP	B-cell_type
of	of	IN	B-PP	O
92	92	CD	B-NP	O
with	with	IN	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
5	5	CD	I-NP	O
%	%	NN	I-NP	O
bands	band	NNS	I-NP	O
.	.	.	O	O

STUDIES	STUDIES	NNS	B-NP	O
:	:	:	O	O
EKG	EKG	NN	B-NP	B-protein
reveals	reveal	VBZ	B-VP	O
sinus	sinus	NN	B-NP	O
bradycardia	bradycardia	NN	I-NP	O
at	at	IN	B-PP	O
50	50	CD	B-NP	O
beats	beat	NNS	I-NP	O
per	per	IN	B-PP	O
minute	minute	NN	B-NP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
axis	axis	NN	I-NP	O
and	and	CC	O	O
normal	normal	JJ	B-NP	O
intervals	interval	NNS	I-NP	O
and	and	CC	O	O
nonspecific	nonspecific	JJ	B-NP	O
ST	ST	NN	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
,	,	,	O	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-NP	O
EKGs	EKG	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
showed	show	VBD	B-VP	O
unchanged	unchanged	JJ	B-NP	O
coarse	coarse	NN	I-NP	O
bilateral	bilateral	JJ	I-NP	O
opacities	opacity	NNS	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
process	process	NN	I-NP	O
.	.	.	O	O

IMPRESSION	IMPRESSION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
76-year-old	76-year-old	JJ	I-NP	O
female	female	NN	I-NP	O
with	with	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
idiopathic	idiopathic	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
fibrosis	fibrosis	NN	I-NP	O
and	and	CC	O	O
cryptogenic	cryptogenic	JJ	B-NP	O
cirrhosis	cirrhosis	NN	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
ascites	ascite	NNS	B-NP	O
and	and	CC	O	O
esophageal	esophageal	JJ	B-NP	O
varices	varix	NNS	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
and	and	CC	I-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
BY	BY	NNP	I-NP	O
SYSTEM	SYSTEM	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
and	and	CC	I-NP	O
sugar	sugar	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
600s	600	NNS	I-NP	B-DNA
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
insulin	insulin	NN	B-NP	B-protein
drip	drip	NN	I-NP	I-protein
at	at	IN	B-PP	I-protein
4	4	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
per	per	IN	B-PP	O
hour	hour	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
sugars	sugar	NNS	I-NP	O
quickly	quickly	RB	B-ADVP	O
normalized	normalize	VBD	B-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
transitioned	transitione	VBN	I-VP	O
over	over	RP	B-PRT	O
to	to	TO	B-PP	O
subcutaneous	subcutaneous	JJ	B-NP	O
insulin	insulin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
that	that	WDT	B-NP	O
included	include	VBD	B-VP	O
Lantus	Lantus	NNP	B-NP	O
and	and	CC	O	O
q.a.c.	q.a.c.	NN	B-NP	O
aspartate	aspartate	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
fingersticks	fingerstick	NNS	I-NP	O
remained	remain	VBD	B-VP	O
labile	labile	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	B-PP	O
at	at	IN	B-PP	O
times	time	NNS	B-NP	O
were	be	VBD	B-VP	O
elevated	elevate	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
300s	300	NNS	I-NP	O
and	and	CC	O	O
other	other	JJ	B-NP	O
times	time	NNS	I-NP	O
were	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
range	range	NN	I-NP	O
of	of	IN	B-PP	O
70	70	CD	B-NP	O
to	to	TO	B-PP	O
90	90	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
insulin	insulin	NN	I-NP	B-protein
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regimen	regimen	NN	I-NP	O
that	that	WDT	B-NP	O
included	include	VBD	B-VP	O
Lantus	Lantus	NNP	B-NP	O
90	90	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
daily	daily	RB	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
aspartate	aspartate	NN	B-NP	O
28	28	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
before	before	IN	B-SBAR	O
each	each	DT	B-NP	O
meal	meal	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
was	be	VBD	B-VP	O
noticed	notice	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
the	the	DT	B-NP	O
most	most	JJS	I-NP	O
difficulty	difficulty	NN	I-NP	O
with	with	IN	B-PP	O
postprandial	postprandial	JJ	B-NP	O
sugars	sugar	NNS	I-NP	O
often	often	RB	B-ADVP	O
after	after	IN	B-PP	O
lunch	lunch	NN	B-NP	O
and	and	CC	I-NP	O
dinner	dinner	NN	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
we	we	PRP	B-NP	O
recommended	recommend	VBD	B-VP	O
that	that	IN	B-SBAR	O
if	if	IN	B-SBAR	O
she	she	PRP	B-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
hyperglycemia	hyperglycemia	NN	B-NP	O
,	,	,	O	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
best	well	RBS	B-VP	O
to	to	TO	I-VP	O
titrate	titrate	VB	I-VP	O
the	the	DT	B-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
aspartate	aspartate	NN	I-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
would	would	MD	B-VP	O
be	be	VB	I-VP	O
best	well	RBS	I-VP	O
to	to	TO	I-VP	O
avoid	avoid	VB	I-VP	O
titrating	titrate	VBG	I-VP	O
the	the	DT	B-NP	O
Lantus	Lantus	NNP	I-NP	O
too	too	RB	B-NP	O
much	much	RB	I-NP	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
fasting	fasting	JJ	I-NP	O
sugar	sugar	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
morning	morning	NN	I-NP	O
was	be	VBD	B-VP	O
often	often	RB	B-ADVP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
hypoglycemic	hypoglycemic	JJ	I-NP	O
episodes	episode	NNS	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
previously	previously	RB	B-ADVP	O
on	on	IN	B-PP	O
q.a.c.	q.a.c.	NN	B-NP	O
insulin	insulin	NN	I-NP	O
dosing	dosing	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
following	follow	VBG	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
that	that	IN	B-SBAR	O
this	this	DT	B-NP	O
would	would	MD	B-VP	O
not	not	RB	I-VP	O
likely	likely	RB	I-VP	O
be	be	VB	I-VP	O
the	the	DT	B-NP	O
best	good	JJS	I-NP	O
regimen	regimen	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP	B-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
discussed	discuss	VBN	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
family	family	NN	I-NP	O
and	and	CC	I-NP	O
caregivers	caregiver	NNS	I-NP	O
who	who	WP	B-NP	O
were	be	VBD	B-VP	O
amenable	amenable	JJ	B-ADJP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
idea	idea	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
will	will	MD	B-VP	O
likely	likely	RB	I-VP	O
need	need	VB	I-VP	O
further	further	JJ	B-NP	O
teaching	teaching	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
cryptogenic	cryptogenic	JJ	B-NP	O
cirrhosis	cirrhosis	NN	I-NP	O
complicated	complicate	VBN	B-VP	O
by	by	IN	B-PP	O
ascites	ascite	NNS	B-NP	O
and	and	CC	O	O
esophageal	esophageal	JJ	B-NP	O
varices	varix	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
grossly	grossly	JJ	B-NP	O
volume	volume	NN	I-NP	O
overloaded	overload	VBD	B-VP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
cirrhosis	cirrhosis	NN	I-NP	O
and	and	CC	I-NP	O
hypoalbuminemia	hypoalbuminemia	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
IV	IV	CD	B-NP	O
Lasix	Lasix	NN	I-NP	O
with	with	IN	B-PP	O
good	good	JJ	B-NP	O
results	result	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
bump	bump	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
aggressive	aggressive	JJ	I-NP	O
diuresis	diuresis	NN	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
Lasix	Lasix	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
but	but	CC	O	O
her	her	PRP$	B-NP	O
oral	oral	JJ	I-NP	O
Lasix	Lasix	NN	I-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
p.o.	p.o.	FW	B-NP	O
Lasix	Lasix	NNP	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
was	be	VBD	B-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
significant	significant	JJ	B-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
ascites	ascite	NNS	B-NP	O
based	base	VBN	B-PP	O
on	on	IN	B-PP	O
abdominal	abdominal	JJ	B-NP	O
exam	exam	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
recently	recently	RB	I-VP	O
completed	complete	VBN	I-VP	O
a	a	DT	B-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
treatment	treatment	NN	B-NP	O
for	for	IN	B-PP	O
spontaneous	spontaneous	JJ	B-NP	O
bacterial	bacterial	JJ	I-NP	O
peritonitis	peritonitis	NN	I-NP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
tenderness	tenderness	NN	I-NP	O
but	but	CC	O	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
distention	distention	NN	B-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
ultrasound	ultrasound	NN	I-NP	O
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
diagnostic	diagnostic	JJ	I-NP	O
paracentesis	paracentesis	NN	I-NP	O
was	be	VBD	B-VP	O
considered	consider	VBN	I-VP	O
given	give	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
confusion	confusion	NN	B-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
abdominal	abdominal	JJ	B-NP	O
ultrasound	ultrasound	NN	I-NP	O
revealed	reveal	VBD	B-VP	O
only	only	RB	B-NP	O
a	a	DT	I-NP	O
small	small	JJ	I-NP	O
lot	lot	NN	I-NP	O
of	of	IN	B-PP	O
ascites	ascite	NNS	B-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
amenable	amenable	JJ	B-ADJP	O
to	to	TO	B-PP	O
paracentesis	paracentesis	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
esophageal	esophageal	JJ	B-NP	O
varices	varix	NNS	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
nadolol	nadolol	NN	I-NP	O
for	for	IN	B-PP	O
prophylaxis	prophylaxis	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
Bactrim	Bactrim	NN	I-NP	O
for	for	IN	B-PP	O
SBP	SBP	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
confusion	confusion	NN	B-NP	O
and	and	CC	I-NP	O
delirium	delirium	NN	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
likely	likely	RB	B-ADJP	O
due	due	IN	B-PP	O
to	to	TO	B-PP	O
hepatic	hepatic	JJ	B-NP	O
encephalopathy	encephalopathy	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
delirium	delirium	NN	I-NP	O
improved	improve	VBD	B-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
initiation	initiation	NN	I-NP	O
of	of	IN	B-PP	O
lactulose	lactulose	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
lactulose	lactulose	NN	B-NP	O
30	30	CD	I-NP	O
mL	mL	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
we	we	PRP	B-NP	O
titrated	titrate	VBD	B-VP	O
so	so	RB	B-SBAR	O
that	that	IN	I-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
at	at	IN	B-NP	O
least	least	JJS	I-NP	O
3	3	CD	I-NP	O
bowel	bowel	NN	I-NP	O
movements	movement	NNS	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
alert	alert	JJ	B-ADJP	O
and	and	CC	O	O
oriented	orient	VBN	B-VP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
Aldactone	Aldactone	NN	B-NP	O
for	for	IN	B-PP	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
overload	overload	NN	I-NP	O
given	give	VBN	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
hyperkalemia	hyperkalemia	NN	B-NP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
elevated	elevated	JJ	B-NP	O
potassium	potassium	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Neurologic	Neurologic	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
had	have	VBN	I-VP	O
one	one	CD	B-NP	O
episode	episode	NN	I-NP	O
of	of	IN	B-PP	O
delirium	delirium	NN	B-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
confused	confuse	VBN	I-VP	O
,	,	,	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
know	know	VB	I-VP	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
interacting	interact	VBG	I-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	B-protein
family	family	NN	I-NP	I-protein
appropriately	appropriately	RB	B-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
workup	workup	NN	I-NP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
included	include	VBD	B-VP	O
an	an	DT	B-NP	O
infectious	infectious	JJ	I-NP	O
workup	workup	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
revealed	reveal	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
infection	infection	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
lactulose	lactulose	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
had	have	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
an	an	DT	B-NP	O
administered	administer	VBN	I-NP	O
initially	initially	RB	B-ADVP	O
by	by	IN	B-PP	O
retention	retention	NN	B-NP	O
enema	enema	NN	I-NP	O
as	as	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
refusing	refuse	VBG	I-VP	O
to	to	TO	I-VP	O
take	take	VB	I-VP	O
p.o.	p.o.	FW	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
mental	mental	JJ	I-NP	O
status	status	NN	I-NP	O
improved	improve	VBD	B-VP	O
within	within	IN	B-PP	O
24	24	CD	B-NP	O
hours	hour	NNS	I-NP	O
of	of	IN	B-PP	O
starting	start	VBG	B-VP	O
the	the	DT	B-NP	O
lactulose	lactulose	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
it	it	PRP	B-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
asterixis	asterixis	NN	I-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.3	1.3	CD	B-NP	O
to	to	TO	B-PP	O
1.7	1.7	CD	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.6	1.6	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
did	do	VBD	B-VP	O
increase	increase	VB	I-VP	O
slightly	slightly	RB	B-ADVP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
diuresis	diuresis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Lasix	Lasix	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
or	or	CC	I-NP	O
two	two	CD	I-NP	O
and	and	CC	O	O
then	then	RB	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
oral	oral	JJ	I-NP	O
home	home	NN	I-NP	O
Lasix	Lasix	NN	I-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
titrated	titrate	VBN	I-VP	O
to	to	TO	B-PP	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
lisinopril	lisinopril	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
hyperkalemia	hyperkalemia	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
lisinopril	lisinopril	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
restarted	restart	VBN	I-VP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
given	give	VBN	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
hyperkalemia	hyperkalemia	NN	B-NP	O
and	and	CC	O	O
several	several	JJ	B-NP	O
episodes	episode	NNS	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
required	require	VBD	B-VP	O
the	the	DT	B-NP	O
administration	administration	NN	I-NP	O
of	of	IN	B-PP	O
Kayexalate	Kayexalate	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
likely	likely	RB	B-ADVP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
on	on	IN	B-PP	O
an	an	DT	B-NP	O
ACE	ACE	NN	I-NP	O
inhibitor	inhibitor	NN	I-NP	O
for	for	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
kidney	kidney	NN	I-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
this	this	DT	B-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
re-added	re-added	JJ	B-ADJP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
with	with	IN	B-PP	O
very	very	RB	B-NP	O
close	close	JJ	I-NP	O
monitoring	monitoring	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
potassium	potassium	NN	I-NP	O
as	as	IN	B-PP	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
indicated	indicate	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
normotensive	normotensive	JJ	B-ADJP	O
off	off	IN	B-PP	O
lisinopril	lisinopril	NN	B-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
IPF	IPF	NN	B-NP	B-protein
and	and	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
pulmonary	pulmonary	JJ	I-NP	O
issues	issue	NNS	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
saturating	saturate	VBG	I-VP	O
well	well	RB	B-ADVP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
O2	O2	NN	B-NP	O
throughout	throughout	IN	B-PP	O
the	the	DT	B-NP	O
entire	entire	JJ	I-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
dexamethasone	dexamethasone	NN	B-NP	O
for	for	IN	B-PP	O
IPF	IPF	NN	B-NP	B-protein
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
Prior	Prior	NN	B-NP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
incidentally	incidentally	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
urine	urine	NN	I-NP	B-cell_line
culture	culture	NN	I-NP	I-cell_line
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
growing	grow	VBG	I-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
100	100	CD	B-NP	O
,	,	,	O	O
000	000	CD	B-NP	O
colonies	colony	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
and	and	CC	O	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
dysuria	dysuria	NN	B-NP	O
but	but	CC	O	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
mildly	mildly	RB	I-NP	O
elevated	elevated	JJ	I-NP	O
white	white	JJ	I-NP	O
count	count	NN	I-NP	O
of	of	IN	B-PP	O
11	11	CD	B-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
.	.	.	O	O

Based	Base	VBN	B-PP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
recent	recent	JJ	I-NP	O
UTI	UTI	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
cefpodoxime	cefpodoxime	NN	B-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
short	short	JJ	I-NP	O
5-day	5-day	JJ	I-NP	O
course	course	NN	I-NP	O
.	.	.	O	O

Results	Result	NNS	B-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
urine	urine	NN	I-NP	O
culture	culture	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
up	up	RP	B-PRT	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
adjusted	adjust	VBN	B-VP	O
as	as	IN	B-PP	O
necessary	necessary	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
Bactrim	Bactrim	NN	I-NP	O
for	for	IN	B-PP	O
both	both	CC	O	O
SPEP	SPEP	NN	B-NP	B-protein
and	and	CC	O	O
PCP	PCP	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
.	.	.	O	O

CODE	CODE	NN	B-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
full	full	JJ	B-NP	O
code	code	NN	I-NP	O
throughout	throughout	IN	B-PP	O
this	this	DT	B-NP	O
entire	entire	JJ	I-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
AT	AT	IN	B-PP	O
THE	THE	DT	B-NP	O
TIME	TIME	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
home	home	NN	I-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
normotensive	normotensive	JJ	I-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
60s	60	NNS	I-NP	B-DNA
to	to	TO	B-PP	I-DNA
70s	70	NNS	B-NP	I-DNA
and	and	CC	O	O
was	be	VBD	B-VP	O
saturating	saturate	VBG	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
high	high	JJ	I-NP	O
90s	90	NNS	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
3	3	CD	I-NP	O
L	L	NN	I-NP	O
of	of	IN	B-PP	O
O2	O2	NN	B-NP	B-protein
via	via	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
cannula	cannula	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
weight	weight	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
was	be	VBD	B-VP	O
198	198	CD	B-NP	O
pounds	pound	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
exam	exam	NN	I-NP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
lungs	lung	NNS	I-NP	O
had	have	VBD	B-VP	O
fine	fine	JJ	B-NP	O
crackles	crackle	NNS	I-NP	O
at	at	IN	B-PP	O
both	both	DT	B-NP	O
bases	base	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
obese	obese	JJ	B-ADJP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
fluid	fluid	NN	I-NP	O
wave	wave	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
extremities	extremity	NNS	I-NP	O
had	have	VBD	B-VP	O
bilateral	bilateral	JJ	B-NP	O
pitting	pit	VBG	I-NP	O
edema	edema	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
knees	knee	NNS	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
asterixis	asterixis	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Cefpodoxime	Cefpodoxime	NN	B-NP	O
200	200	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
daily	daily	JJ	B-NP	O
times	time	NNS	I-NP	O
5	5	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
after	after	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
dose	dose	NN	I-NP	O
on	on	IN	B-PP	O
10/1/07	10/1/07	CD	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Fosamax	Fosamax	NN	B-NP	O
35	35	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
weekly	weekly	RB	I-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Artificial	Artificial	JJ	B-NP	O
tears	tear	NNS	I-NP	O
2	2	CD	B-NP	O
drops	drop	NNS	I-NP	O
to	to	TO	B-PP	O
both	both	DT	B-NP	O
eyes	eye	NNS	I-NP	O
3	3	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
dryness	dryness	NN	B-NP	O
or	or	CC	I-NP	O
irritation	irritation	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Caltrate	Caltrate	NNP	B-NP	O
600	600	CD	I-NP	O
plus	plus	CC	O	O
D	D	NN	B-NP	O
1	1	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Clotrimazole	Clotrimazole	NN	B-NP	O
troche	troche	NN	I-NP	O
topically	topically	RB	B-ADVP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
mouth	mouth	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Dexamethasone	Dexamethasone	NN	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Colace	Colace	NNP	B-NP	O
100	100	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Lovenox	Lovenox	NN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
once	once	RB	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
ambulating	ambulate	VBG	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
basis	basis	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Aspartate	Aspartate	NN	B-NP	O
insulin	insulin	NN	I-NP	O
20	20	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
q.a.c.	q.a.c.	RB	B-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Insulin	Insulin	NN	B-NP	O
aspartate	aspartate	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
q.a.c.	q.a.c.	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Lantus	Lantus	NNP	B-NP	O
90	90	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
q.a.m.	q.a.m.	RB	B-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Combivent	Combivent	VB	B-VP	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.i.d.	q.i.d.	NN	B-NP	O
14	14	CD	I-NP	O
.	.	.	O	O

Lactulose	Lactulose	RB	B-NP	O
30	30	CD	I-NP	O
mL	mL	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
held	hold	VBN	I-VP	O
if	if	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
having	have	VBG	I-VP	O
greater	great	JJR	B-NP	O
than	than	IN	I-NP	O
3	3	CD	I-NP	O
bowel	bowel	NN	I-NP	O
movements	movement	NNS	I-NP	O
daily	daily	RB	B-ADVP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Miconazole	Miconazole	NN	B-NP	O
powder	powder	NN	I-NP	O
applied	apply	VBD	B-VP	O
topically	topically	RB	B-ADVP	O
to	to	TO	B-PP	O
affected	affect	VBN	B-NP	O
area	area	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Nadolol	Nadolol	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
24h	24h	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Prilosec	Prilosec	RB	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Bactrim	Bactrim	NN	B-NP	O
1	1	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.	q.	NN	I-NP	O
24h	24h	NN	I-NP	O
.	.	.	O	O

FOLLOW-UP	FOLLOW-UP	NN	B-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
weight	weight	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
was	be	VBD	B-VP	O
198	198	CD	B-NP	O
kg	kg	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
weighed	weigh	VBN	I-VP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
contacted	contact	VBN	I-VP	O
for	for	IN	B-PP	O
any	any	DT	B-NP	O
weight	weight	NN	I-NP	O
gain	gain	NN	I-NP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
5	5	CD	B-NP	O
pounds	pound	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
chem-7	chem-7	NN	I-NP	O
checked	check	VBD	B-VP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
2	2	CD	I-NP	O
to	to	TO	I-NP	O
3	3	CD	I-NP	O
days	day	NNS	I-NP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
her	her	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
her	her	PRP$	B-NP	O
potassium	potassium	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
urine	urine	NN	I-NP	O
culture	culture	NN	I-NP	O
sent	send	VBD	B-VP	O
prior	prior	JJ	B-ADJP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
that	that	DT	B-NP	O
revealed	reveal	VBD	B-VP	O
100	100	CD	B-NP	O
,	,	,	O	O
000	000	CD	B-NP	O
colonies	colony	NNS	I-NP	O
of	of	IN	B-PP	O
bacteria	bacteria	NNS	B-NP	O
that	that	WDT	B-NP	O
were	be	VBD	B-VP	O
not	not	RB	I-VP	O
yet	yet	RB	I-VP	O
identified	identify	VBN	I-VP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
time	time	NN	I-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
started	start	VBN	I-VP	O
empirically	empirically	RB	B-ADVP	O
on	on	IN	B-PP	O
cefpodoxime	cefpodoxime	NN	B-NP	O
based	base	VBN	B-VP	O
on	on	IN	B-PP	O
past	past	JJ	B-NP	O
microbiologic	microbiologic	JJ	I-NP	O
data	datum	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
results	result	NNS	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
urine	urine	NN	I-NP	B-cell_line
culture	culture	NN	I-NP	I-cell_line
should	should	MD	B-VP	O
be	be	VB	I-VP	O
followed	follow	VBN	I-VP	O
up	up	RP	B-PRT	O
in	in	IN	B-PP	O
a	a	DT	B-NP	O
day	day	NN	I-NP	O
or	or	CC	I-NP	O
two	two	CD	I-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
antibiotics	antibiotic	NNS	I-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
adjusted	adjust	VBN	I-VP	O
as	as	IN	B-PP	O
necessary	necessary	JJ	B-ADJP	O
.	.	.	O	O

FOLLOW-UP	FOLLOW-UP	NN	B-NP	O
APPOINTMENT	APPOINTMENT	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
appointment	appointment	NN	B-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
gastroenterologist	gastroenterologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Darbonne	Darbonne	NNP	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
3/6/07	3/6/07	CD	B-NP	O
at	at	IN	B-PP	O
2	2	CD	B-NP	O
:	:	SYM	O	O
20	20	CD	B-NP	O
p.m.	p.m.	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
afternoon	afternoon	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
follow-up	follow-up	JJ	B-NP	O
appointment	appointment	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Frush	Frush	NNP	I-NP	O
,	,	,	O	O
on	on	IN	B-PP	O
10/26/07	10/26/07	CD	B-NP	O
at	at	IN	B-PP	O
10	10	CD	B-NP	O
:	:	:	O	O
15	15	CD	B-NP	O
.	.	.	O	O

DISPOSITION	DISPOSITION	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
8-3359430	8-3359430	CD	B-NP	O
SSSten	SSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Elmer	Elmer	NNP	B-NP	O
Capobianco	Capobianco	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Sonry	Sonry	NNP	I-NP	O
Orttar	Orttar	NNP	I-NP	O
General	General	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
A	A	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Orlando	Orlando	NNP	B-NP	O
Gino	Gino	NNP	I-NP	O
Figart	Figart	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Wayne	Wayne	NNP	B-NP	O
Safranek	Safranek	NNP	I-NP	O
,	,	,	O	O
MD	MD	NNP	B-NP	O
Niry	Niry	NNP	I-NP	O
Tiagrea	Tiagrea	NNP	I-NP	O
General	General	NNP	I-NP	O
Healthcare	Healthcare	NNP	I-NP	O
Spo	Spo	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
GILBERT	GILBERT	NN	B-NP	O
,	,	,	O	O
GEOFFREY	GEOFFREY	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
MEZO	MEZO	NNP	B-NP	O
,	,	,	O	O
NEIL	NEIL	NNP	B-NP	O
PHIL	PHIL	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
6599799	6599799	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
3/16/07	3/16/07	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
3/16/07	3/16/07	CD	B-NP	O

